𝔖 Bobbio Scriptorium
✦   LIBER   ✦

550 REPLICATIVE CAPACITY OF ENTECAVIR-RESISTANT HEPATITIS B VIRUS MUTANTS IN HBeAg-NEGATIVE HEPATITIS B

✍ Scribed by S. Amini-Bavil-Olyaee; C. Trautwein; F. Tacke

Book ID
117377559
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
67 KB
Volume
50
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in the prevalence of HBeAg-negat
Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B
✍ Keisuke Hamasaki; Keisuke Nakata; Yuji Nagayama; Akira Ohtsuru; Manabu Daikoku; 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 683 KB

Hepatitis B virus with a G-to-A point mutation at nucleotide 83 in the precore region (mutant hepatitis B virus 83), which cannot produce HBeAg, is commonly found in HBe antibody-positive hepatitis B virus carriers. We analyzed the consecutive changes in the prevalence of mutant hepatitis B virus 83

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60